Skip to main content

Table 1 Correlation between KSR2 levels in 198 HCC patients and their clinicopathologic characteristics

From: KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma

Variate

n

KSR2 expression

Low

High

p value

Age

   

0.200

  < 53

103

47

56

  ≥ 53

95

52

43

Gender

   

1.000

 Male

170

85

85

 Female

28

14

14

HBsAg

   

0.852

 No

35

17

18

 Yes

163

82

81

Anti-HCV

   

0.902

 No

7

4

3

 Yes

191

95

96

Liver cirrhosis

   

0.817

 No

21

11

10

 Yes

177

88

89

AFP

   

0.769

  < 20 ng/mL

74

36

38

  ≥ 20 ng/mL

124

63

61

ALT

   

0.540

  ≤ 50 U/L

136

70

66

 

  > 50 U/L

62

29

33

 

GGT

   

1.000

  ≤ 60 U/L

112

56

56

 

  > 60 U/L

86

43

43

 

Number of tumors

   

0.182

 1

165

79

86

  > 1

33

20

13

Tumor size

   

0.032

  < 5 cm

111

63

48

  ≥ 5 cm

87

36

51

Tumor differentiation

   

0.752

 good /middle

142

70

72

 poor

56

29

27

Tumor capsule

   

0.670

 No

95

49

46

 Yes

103

50

53

Stage

   

0.641

 I

139

71

68

 II

59

28

31